Drugs

Of the 12,203 drugs in the pipeline, 5,319 were in Phase 1 while 4,979 were in Phase 2. In addition, there were 1,671 Phase 3 drugs and 234 in the pre-registration stage.

The company says it expects the RSV vaccine—called mRESVIA—to be available in early 2025.

The injectable monoclonal antibody prevents respiratory syncytial virus in newborns and infants during their first RSV season and at-risk children during their second RSV season.

Get the info you need on these new indications as part of our drug news roundup for October.

Get the info you need on this new product, part of our drug news roundup for October.

Get the info you need on this new product, part of our drug news roundup for October.

Get the info you need on this new dosage for as part of our drug news roundup for October.

Take note of this Health Canada advisory as part of our October drug news update.